Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
about
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.Inertial Sensors to Assess Gait Quality in Patients with Neurological Disorders: A Systematic Review of Technical and Analytical ChallengesBenzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.Attentional Control of Gait and Falls: Is Cholinergic Dysfunction a Common Substrate in the Elderly and Parkinson's Disease?Direct and indirect effects of attention and visual function on gait impairment in Parkinson's disease: influence of task and turning.Predictors of Recurrent Falls in People with Parkinson's Disease and Proposal for a Predictive Tool.A clinical view on the development of technology-based tools in managing Parkinson's disease.Aging, the Central Nervous System, and Mobility in Older Adults: Interventions.Pharmacological treatment in Parkinson's disease: Effects on gait.Freezing of gait in Parkinson's disease: from pathophysiology to emerging therapies.Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study.The brain map of gait variability in aging, cognitive impairment and dementia-A systematic review.Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naïve cohort.Autonomous Quality Control of Joint Orientation Measured with Inertial Sensors.Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back.Wearable sensors objectively measure gait parameters in Parkinson's disease.Exploring Associations Between Postural Balance and Levels of Urinary Organophosphorus Pesticide Metabolites.How Wearable Sensors Can Support Parkinson's Disease Diagnosis and Treatment: A Systematic Review.Gait, posture and cognition in Parkinson's disease.Falls in Parkinson's disease: A complex and evolving picture.Falls in Cognitively Impaired Older Adults: Implications for Risk Assessment And Prevention.Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'.Gait Rather Than Cognition Predicts Decline in Specific Cognitive Domains in Early Parkinson's Disease.Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.Tai Chi for Reducing Dual-task Gait Variability, a Potential Mediator of Fall Risk in Parkinson's Disease: A Pilot Randomized Controlled Trial.Quantifying Motor Impairment in Movement Disorders.SPARC: a new approach to quantifying gait smoothness in patients with Parkinson's disease.Cognitive Involvement in Balance, Gait and Dual-Tasking in Aging: A Focused Review From a Neuroscience of Aging PerspectiveCholinergic Pathway SNPs and Postural Control in 477 Older Adults
P2860
Q30244035-71846555-DF56-4BD4-AD54-BE66957B876DQ30851350-1112BA2B-812D-424A-907D-CD37EA03012FQ31154313-C217CAA2-DC1F-47E1-A359-E946964E14D2Q33574058-4CBBC590-5FCA-4A47-81DD-01D9BBC1D4E8Q36881389-275E6F89-8A27-4C4D-8D58-9E300B746068Q38690675-3BCA868D-06D7-4504-BEC7-FADE9C63AF89Q38754863-940E6C24-C25C-4D4E-AD77-4E51BB392AC4Q38858508-53C0226E-993F-4B3B-A36F-DA09A5CE5F3EQ38870377-04ECAFFC-B943-4A05-9159-8B7C46F23DB8Q38909702-FBFC7897-8DE0-409B-BF2D-47881CE2EB03Q38947418-70792783-49B4-4ACB-BC07-FB399824DC98Q39079510-EA8B9FBA-F298-4074-B912-19FC1269FEF0Q39099400-0B88874A-79BE-4F7E-97B2-95C9E000C54AQ39398312-C2F475AE-86FF-41E9-B3D4-37955F39CEDDQ39614456-63B0A10A-F3B0-4087-B900-5AE86D9A402BQ41475368-7E36C18E-2DFA-4D0A-B5D4-9AA1D666650BQ42705320-6CCF4E3A-0A80-4D82-85AC-514F6F8524B0Q45069850-148706A6-8DC2-4BFF-BDB3-39A9533D6ECCQ47112423-CAF666A1-79C4-4029-BDD7-C3E51CAC1D48Q47142760-0C0A619A-5547-4524-898F-CA92F32E239EQ47631495-9E779EE8-7C45-4BE3-8EB0-39202CBD5662Q47741540-BBEA6D35-98CF-4EF0-A8AC-005767AE9BCEQ48175839-0E22F967-0E20-4D91-83C3-359678E8E20AQ48370307-6EC06E80-78B6-453D-9EC9-39AE6CFE1FFAQ50584947-09A1108E-9F6F-410A-A3DC-04819C718116Q52734704-CEC3423C-85F5-4BD3-8B00-34359B2E749CQ54958506-2E1EDB64-45BD-4800-8129-9252911175F7Q55153472-DD8D7149-782B-48D7-8318-6AFDFA1FC9BBQ55244629-7023AC91-5B7E-455B-A5EE-D9DD539B5FACQ55365379-11E19AFF-2155-4BF6-9E4F-2976D6155DBBQ58693561-2969286C-F0FB-406F-9FD8-B5F9BC32805BQ58764758-A2A8DAB2-48DB-43DB-9CBB-94165D03605E
P2860
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@en
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@nl
type
label
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@en
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@nl
prefLabel
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@en
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@nl
P50
P921
P1433
P1476
Rivastigmine for gait stabilit ...... ebo-controlled, phase 2 trial.
@en
P2093
Andrew D Lawrence
Jacqueline C T Close
P304
P356
10.1016/S1474-4422(15)00389-0
P577
2016-01-12T00:00:00Z